Formulation Development
PolTREG Receives US Patent Office Notice of Allowance for Treg Cell Therapy to Treat Type-1 Diabetes
PolTREG S.A. recently announced it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO), covering the manufacturing of T-regulatory cells…
Intravacc Awarded CARB-X Funding to Develop Vaccine That Prevents Gonorrhea Infections
Intravacc recently announced it has been awarded a funding that may total $633K from CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) a global non-profit organization, for the….
Revive Therapeutics Provides Update Evaluating Bucillamine for Nerve Agent Exposure With Defence Research & Development Canada
Revive Therapeutics Ltd. recently announced an update on its project evaluating Bucillamine as a potential treatment for nerve agent exposure with Defence R&D Canada –…
Anavex Life Sciences Announces US Phase 2 Clinical Trial of ANAVEX3-71 in Schizophrenia
Anavex Life Sciences Corp. recently announced the initiation of the US FDA cleared placebo-controlled Phase 2 trial of ANAVEX3-71 for the treatment of schizophrenia, which…
Santhera Launches Vamorolone in Germany as First Market for the Treatment of Duchenne Muscular Dystrophy
Santhera Pharmaceuticals recently announced the launch of AGAMREE (vamorolone) for the treatment of Duchenne muscular dystrophy (DMD) in patients 4 years of age and older,…
ExeVir Bio Announces Positive Virus Neutralization Data for XVR012 Against Emerging COVID-19 Omicron Variants
ExeVir Bio recently announced new data demonstrating that its antibodies are highly potent in neutralizing currently circulating COVID-19 Omicron variants. All authorized SARS-CoV-2 therapeutic antibodies…
Henlius & Sermonix Announce Strategic Collaboration & Exclusive License Agreements for Novel Endocrine Therapy Lasofoxifene
Sermonix Pharmaceuticals Inc. and Shanghai Henlius Biotech, Inc. recently announced a strategic collaboration agreement in which Henlius will receive exclusive rights to develop, manufacture, and…
STADA & Alvotech Secure Approval for Europe’s First Ustekinumab Biosimilar to Stelara
Partners STADA and Alvotech recently announced the European Commission issued a marketing authorization for Uzpruvo (AVT04), a biosimilar candidate to Stelara (ustekinumab). The centralized marketing….
Revive Therapeutics Successfully Completes Development of a Novel Lyophilized Formulation of Bucillamine
Revive Therapeutics Ltd. recently announced it has completed the formulation development work of its next-generation lyophilized formulation of Bucillamine (New Bucillamine) conducted at the University…
Verge Genomics Announces Initiation of Proof-of-Concept Study for the Treatment of Amyotrophic ALS
Verge Genomics recently announced the initiation of its Phase 1b proof-of-concept study of VRG50635 for the treatment of sporadic and familial forms of amyotrophic lateral…
Lexaria Bioscience Improves Delivery, Efficacy of GLP-1 Agonists Through Proprietary Drug Delivery Platform
Lexaria Bioscience Corp. recently announced its placement in an editorial published by NetworkNewsWire (NNW), one of 60+ brands within the….
Nanoform Commenced Relative Bioavailability Study of Nanotechnology-Enhanced Enzalutamide
Nanoform Finland Plc recently announced it had completed the First Subject First Visit (FSFV) in a trial to evaluate the relative bioavailability of its nanocrystalline…
Enzene Biosciences Launches its First Manufacturing Base in the US, With Additional Plans to Establish Continuous Manufacturing Operations at its New Jersey Site
Widely recognized as a pioneer in continuous manufacturing, Pune-based Contract Development & Manufacturing Organization (CDMO), Enzene Biosciences has announced the launch of its first manufacturing site in the US, located in….
Biora Therapeutics Announces Initiation of Phase 1 Clinical Study for Drug-Device combination Program
Biora Therapeutics, Inc. recently announced initiation of its Phase 1, first-in-human clinical study of BT-600 in healthy adult volunteers. BT-600 is a drug-device combination program consisting of the orally….
Olema Oncology Nominates Orally Bioavailable KAT6 Inhibitor as a Development Candidate
Olema Pharmaceuticals, Inc. recently announced the selection of a development candidate for the its program targeting KAT6, an epigenetic target that is dysregulated in breast…
Artelo Biosciences Announces Selection of Worldwide Clinical Trials as CRO to Support First-in-Human Study
Artelo Biosciences, Inc. recently announced it has selected Worldwide Clinical Trials to support the its planned Phase 1 trial with ART26.12, its Fatty Acid Binding…
CordenPharma & pHLIP Announce Strategic Alliance to Develop pHLIP LNP Targeted Delivery Platform for RNA & Gene Therapies
CordenPharma International and pHLIP, Inc. recently announce their strategic alliance to collaborate in developing and commercializing the pHLIP-LNP targeted delivery platform for RNA-based and genetic…
Sitryx Announces Collaboration Partner Lilly Has Commenced Phase 1 Study of SIT-011 for Chronic Autoimmune & Inflammatory Diseases
Sitryx Therapeutics recently announced Eli Lilly & Company has commenced a Phase 1 first-in-human study of SIT-011, a post-translational modification modulator program for chronic autoimmune and….
Boehringer Ingelheim Licenses Multiple Dark Antigens From Enara Bio to Develop Off-the-Shelf Immunotherapies for Non-Small Cell Lung Cancer
Enara Bio recently announced Boehringer Ingelheim has exercised its option to license a number of cancer antigens discovered and validated through the ongoing collaboration using…
Gerresheimer & Aptar Digital Health Collaborate to Develop Integrated Solution for Cancer Therapy
Gerresheimer and Aptar Digital Health recently announced they will collaborate to develop an integrated solution for cancer therapy management. As part of this collaboration….
